𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Identification of alpha-actinin 4 and 67 kDa laminin receptor as stage-specific markers in esophageal cancer via proteomic approaches

✍ Scribed by Li Fu; Yan Ru Qin; Dan Xie; Hoi Yee Chow; Sai Ming Ngai; Dora L. W. Kwong; Yan Li; Xin Yuan Guan


Book ID
102805242
Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
702 KB
Volume
110
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

BACKGROUND.

Esophageal squamous cell carcinoma (ESCC) is one of the most common malignancies in the world with a very poor prognosis. The majority of ESCC patients present with advanced metastatic disease upon diagnosis. Therefore, it is important to understand the molecular mechanism in the tumor invasion process and to find new biomarkers for early diagnosis and prognostic evaluation.

METHODS.

Differentially expressed proteins among different stages of primary ESCCs and their matched surrounding normal tissues were compared by proteomics‐based technology. The correlations between interesting proteins and clinical features of ESCC were further investigated by using ESCC tissue microarray (TMA) by immunohistochemical staining.

RESULTS.

Compared with normal tissues, a total of 18 differentially expressed proteins were identified in ESCC in this study. Among them, expression levels of alpha‐actinin 4 (ACTN4) and 67 kDa laminin receptor (67LR) were progressively increased from stage I to III. Clinicopathological correlation using TMA revealed that overexpression of ACTN4 was significantly associated with advanced tumor stage (P = .026) and lymph node metastasis (P = .049), whereas overexpression of 67LR was significantly correlated with advanced tumor stage (P = .019) but not lymph node metastasis.

CONCLUSIONS.

These findings suggested that overexpression of ACTN4 and 67 LR is associated with ESCC progression and that these biomarkers may potentially be useful to prognostic evaluation, molecular biological classification, and therapeutic targeting. Cancer 2007. © 2007 American Cancer Society.